Financing Round Led by Perceptive Advisors Three Clinical Trials Expected to Commence in the First Half of 2019, Including Two Late-Stage Rare Oncology Programs and First Targeted Oncology Program in Collaboration with BeiGene STAMFORD, Conn., April 1, 2019-- SpringWorks Therapeutics, Inc. (the “Company”), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced the closing of a $125 million Series B preferred stock financing led by Perceptive Advisors.